Traders should monitor the ATS conference presentation on May 20 for initial data on agenT-797's immune restoration potential in severe infections, which could influence near-term sentiment. Until then, no material change in valuation is supported.
INKT drugs
INKT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 1 $10.57entry
- T+1 · 8mo ago +1.14%α +1.06% · $10.69
- T+5 · 7mo ago +8.51%α +4.75% · $11.47
- T+20 · 7mo ago +11.73%α +2.01% · $11.81
- T+60 · 5mo ago +12.68%α −0.70% · $11.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, in combination with N-803 for severe Coccidioides infection, has been accepted for presentation at the ATS International Conference in May 2026. No data will be disclosed ahead of the conference, and full results will be shared during the poster session. This represents early-stage clinical visibility but no new efficacy or safety results.
Key Facts
- Abstract on agenT-797 combination therapy accepted for poster presentation at ATS 2026 conference.
- Presentation will occur on May 20, 2026, in Orlando, Florida; no data released in advance.
- agenT-797 is in clinical development for GvHD, solid tumors, and severe pulmonary inflammation.
- No financial or clinical results disclosed; next update expected at the conference.
Financial Impact
No immediate financial impact; potential for sentiment shift post-data disclosure
Risk Factors
- No data available yet, clinical benefit remains unproven
- High risk typical of early-stage biotech development; future results may not meet expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266508 |
Track record
21 reports on INKT
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers